Peptide Stacking Protocols: Advanced Combination Research Guide [2026]

Peptide Stacking Protocols: The Definitive 2026 Guide to Advanced Combination Research

The science of peptide stacking protocols represents one of the most sophisticated frontiers in peptide research. While individual peptides produce meaningful biological effects through their respective mechanisms, the strategic combination of complementary compounds can unlock synergistic outcomes that far exceed the sum of their individual contributions. Understanding which peptides stack synergistically, which are merely additive, and which are potentially antagonistic is essential knowledge for any advanced peptide researcher.

This comprehensive guide covers the pharmacological foundations of peptide stacking, presents evidence-based combination protocols for every major research goal, provides detailed timing blueprints, addresses cost optimization strategies, and identifies contraindicated combinations that researchers must avoid. Whether you are building your first two-peptide combination or designing a complex multi-compound protocol, the principles outlined here will serve as your definitive reference for peptide stacking protocols in 2026 and beyond.

For those new to peptide research, we recommend first reviewing our peptide research for beginners guide and foundational peptide stacking guide before diving into the advanced protocols covered here.

Chapter 1: The Science of Peptide Stacking — Synergy, Additivity, and Antagonism

1.1 Defining Interaction Types

When two or more peptides are administered concurrently, their combined effect falls into one of three categories, each with distinct pharmacological implications:

• Synergistic interaction — The combined effect exceeds the mathematical sum of each compound’s individual effect. Example: CJC-1295 (GHRH pathway) + Ipamorelin (ghrelin pathway) produces GH release 2–3× greater than the sum of each compound administered alone, because they stimulate the same endpoint (GH release) through independent, complementary receptor pathways that converge on pituitary somatotroph activation (PMID: 16352683).
• Additive interaction — The combined effect approximately equals the sum of each compound’s individual effect. Example: BPC-157 (angiogenesis + nitric oxide modulation) + GHK-Cu (copper-dependent matrix remodeling) produce complementary but mechanistically independent tissue-repair effects that sum together without true synergy.
• Antagonistic interaction — The combined effect is less than the sum (or even less than either compound alone). Example: a GHRH analog administered concurrently with somatostatin or a somatostatin analog directly opposes the intended GH-releasing effect, producing functional antagonism.

1.2 Receptor Crosstalk and Pathway Complementarity

The most effective peptide stacking protocols exploit receptor crosstalk — the phenomenon where activation of one receptor system amplifies signaling through another. The GH secretagogue field provides the clearest example: GHRH receptors and GHS-R1a (ghrelin receptors) on pituitary somatotrophs signal through different G-protein coupled pathways (Gs/cAMP/PKA for GHRH-R vs. Gq/PLC/IP3/Ca²? for GHS-R1a), but both pathways converge on intracellular calcium mobilization required for GH granule exocytosis (PMID: 9849822).

The cAMP elevation from GHRH-R activation sensitizes calcium channels that are subsequently opened by IP3 from GHS-R1a activation, creating a multiplicative increase in calcium influx and GH release. This is true pharmacological synergy arising from pathway complementarity, and it is the gold standard that advanced stacking protocols attempt to replicate across other target systems.

Beyond GH secretagogues, pathway complementarity drives synergy in tissue repair stacks (BPC-157’s nitric oxide and VEGF modulation + TB-500’s actin polymerization and cell migration), fat loss stacks (GLP-1-mediated appetite suppression + GH-mediated lipolysis + MOTS-c-mediated AMPK activation), and cognitive stacks (Semax’s BDNF upregulation + IGF-1-mediated neurogenesis).

1.3 Understanding Receptor Saturation

A critical concept for stacking protocol design is receptor saturation — the dose at which additional ligand produces no incremental receptor activation because all available receptors are occupied. Each receptor system has a finite number of binding sites, and exceeding saturation dosing wastes compound without improving outcomes while potentially increasing off-target effects.

For GH secretagogues, pituitary GHS-R1a saturation occurs at approximately 1–2 µg/kg for Ipamorelin and GHRH-R saturation at approximately 1 µg/kg for CJC-1295. Beyond these doses, adding more of the same compound produces minimal incremental GH release (the dose-response curve plateaus). However, adding a compound that acts through a different receptor (e.g., adding Ipamorelin to a saturating dose of CJC-1295) produces additional response because the second compound activates a distinct, unsaturated receptor population. This principle of targeting multiple unsaturated receptors simultaneously is the foundation of effective stacking.

1.4 Diminishing Returns and the Complexity Ceiling

While two-compound stacks frequently demonstrate clear synergy, adding a third, fourth, or fifth compound to a stack typically produces diminishing returns. This occurs because downstream signaling pathways converge on shared effectors (e.g., mTOR for anabolic signaling, NF-?B for inflammatory regulation), and these shared nodes become rate-limiting regardless of how many upstream pathways are simultaneously activated. As a general principle, two to three well-chosen peptides targeting distinct pathways will capture 80–90% of the achievable effect, with additional compounds adding marginal benefit at increasing cost and complexity. For a detailed framework on combining peptides effectively, consult our peptide stacking guide.

Chapter 2: Fundamental Stacking Rules

2.1 Timing and Spacing

Proper timing is among the most critical and most frequently misunderstood aspects of peptide stacking protocols. Key timing principles include:

• Same-syringe compatibility — Peptides targeting the same tissue or receptor system at the same time can often be combined in a single injection to reduce injection burden. CJC-1295 + Ipamorelin is the classic example; these two peptides are chemically compatible and pharmacologically synergistic when co-administered.
• Fasting requirement — GH secretagogues should be administered on an empty stomach (minimum 2 hours fasted) because insulin and free fatty acids suppress GH release. Eating within 30 minutes of GH secretagogue administration blunts the GH pulse by 50–70%, dramatically reducing IGF-1 elevation (PMID: 18981485).
• GLP-1 agonist timing — Semaglutide and other GLP-1 agonists are typically administered weekly (for long-acting forms) or daily, independent of meals. Their mechanism (GLP-1 receptor agonism) does not conflict with GH secretagogue timing.
• Healing peptide timing — BPC-157 and TB-500 can be administered at any time relative to meals, as their mechanisms are not insulin-sensitive. For localized injury, injection near the injury site provides higher local concentrations.
• Spacing competing pathways — Compounds that activate opposing pathways should be temporally separated. For example, MOTS-c (AMPK activator, which inhibits mTOR) should be administered at least 4–6 hours away from GH secretagogues (which work partly through mTOR activation for anabolic effects) to avoid signaling interference.

2.2 Injection Site Considerations

Subcutaneous injection is the standard route for most peptides. When administering multiple peptides, rotating injection sites (abdomen, deltoid, thigh) reduces local tissue irritation. For healing peptides like BPC-157, subcutaneous injection near the injury site can increase local bioavailability, though systemic absorption from any injection site provides distribution to the injury via circulation. All peptides should be reconstituted with bacteriostatic water per our peptide reconstitution masterclass.

2.3 The 80/20 Rule of Stacking

For most research goals, 80% of achievable results come from 2–3 well-chosen compounds. Adding compounds beyond this core produces diminishing returns while increasing cost, injection burden, and the complexity of monitoring side effects and attributing outcomes. Researchers should master a core 2-peptide stack before adding additional compounds, and each addition should have clear mechanistic justification rather than simply adding “more peptides.”

Chapter 3: The Growth Hormone Stack

3.1 CJC-1295 + Ipamorelin — The Gold Standard

The CJC-1295 + Ipamorelin combination is the most widely researched and best-characterized peptide stack in existence. As detailed in our growth hormone secretagogues complete guide, the synergy between GHRH-pathway (CJC-1295) and ghrelin-pathway (Ipamorelin) stimulation produces GH pulses 2–3× greater than either compound alone.

Protocol Details

Parameter	Conservative Protocol	Standard Protocol	Aggressive Protocol
CJC-1295 (no DAC)	100 µg 1×/day	100 µg 2×/day	100 µg 3×/day
Ipamorelin	100 µg 1×/day	200 µg 2×/day	300 µg 3×/day
Timing	Before bed (fasted)	AM fasted + before bed	AM + afternoon + before bed
Expected GH increase	2–3× pulse amplitude	3–5× pulse amplitude	4–6× pulse amplitude
Expected IGF-1 increase	1.3–1.6×	1.5–2.0×	1.8–2.5×
Recommended duration	12–16 weeks	12–16 weeks	8–12 weeks

The pre-bed administration timing capitalizes on the natural nocturnal GH surge during slow-wave sleep, amplifying an existing physiological pulse rather than creating an unphysiological one. For the twice-daily protocol, the morning dose should be administered upon waking after an overnight fast, with breakfast delayed 30–45 minutes post-injection. Dosing calculations can be confirmed using our peptide dosage calculator.

3.2 Adding Tesamorelin for Maximum GHRH Stimulation

Tesamorelin is a full-length 44-amino acid GHRH analog (vs. CJC-1295’s 29 amino acids), potentially providing more complete GHRH receptor activation. In clinical trials, Tesamorelin at 2 mg daily produced IGF-1 increases of 1.5–1.7× baseline with concurrent reductions in visceral adipose tissue of 15–18% (PMID: 17956947).

For researchers seeking maximum GH axis stimulation, Tesamorelin can replace CJC-1295 in the gold standard stack or be added as a third compound:

• Replacement protocol: Tesamorelin 1–2 mg + Ipamorelin 200 µg, administered before bed. Expected IGF-1 increase: 1.6–2.3×.
• Triple-axis protocol: CJC-1295 100 µg (morning) + Tesamorelin 1 mg (evening) + Ipamorelin 200 µg (both morning and evening). This provides continuous GHRH pathway coverage with dual-timepoint ghrelin stimulation. Expected IGF-1 increase: 2.0–2.8×.

Note that the triple-axis protocol represents an aggressive approach with diminishing returns beyond the standard dual protocol. The additional IGF-1 elevation must be weighed against increased cost and injection burden.

3.3 MK-677 Considerations

MK-677 (Ibutamoren) is an oral ghrelin mimetic that provides 24-hour GH/IGF-1 elevation from a single daily dose. While not a peptide, it is commonly included in GH-focused peptide stacking protocols. A two-year study in healthy elderly adults demonstrated sustained IGF-1 elevation of approximately 40% above baseline at 25 mg/day without tachyphylaxis (PMID: 18981485).

When considering MK-677 as a stack component, researchers must account for its metabolic effects: increased fasting glucose (5–8 mg/dL), elevated fasting insulin (20–40%), appetite stimulation, and water retention. These effects may be acceptable in a pure GH/IGF-1 optimization context but can be counterproductive when stacking with fat loss peptides. For researchers prioritizing metabolic cleanliness, injectable GH secretagogues (CJC-1295 + Ipamorelin) are preferable despite the injection requirement.

Chapter 4: The Healing Stack

4.1 BPC-157 + TB-500 — The Wolverine Stack

The BPC-157 + TB-500 combination (commonly called the “Wolverine Stack”) is the most popular healing-focused peptide stack, and for good reason — these two peptides operate through entirely distinct but complementary tissue-repair mechanisms, producing what research suggests is a synergistic healing response.

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from human gastric juice that promotes healing through nitric oxide system modulation, VEGF-mediated angiogenesis, growth factor upregulation (EGF, FGF, TGF-?), and anti-inflammatory NF-?B pathway modulation. It has demonstrated remarkable tissue-repair effects across virtually every tissue type studied — tendon, ligament, muscle, bone, skin, gut, nerve, and vascular tissue (PMID: 29713866). For complete coverage of BPC-157’s mechanisms, see our BPC-157 peptide research guide.

TB-500 (Thymosin Beta-4 fragment) promotes healing through a fundamentally different mechanism: it sequesters G-actin monomers, promoting actin polymerization and cytoskeletal reorganization necessary for cell migration into wound sites. TB-500 also upregulates laminin-5 (for cell adhesion and migration), reduces inflammatory cytokines, and promotes hair follicle stem cell migration for tissue regeneration (PMID: 20615549). Our TB-500 research guide provides a comprehensive mechanism review.

For detailed stacking protocols and the complete evidence base for this combination, see our BPC-157 + TB-500 Wolverine stack guide.

Wolverine Stack Protocol

Phase	BPC-157 Dose	TB-500 Dose	Frequency	Duration
Loading (acute injury)	250–500 µg	2.0–2.5 mg	2×/day (BPC), 2×/week (TB)	2–4 weeks
Healing (sub-acute)	250 µg	2.0 mg	1×/day (BPC), 2×/week (TB)	4–8 weeks
Maintenance	250 µg	1.0 mg	1×/day (BPC), 1×/week (TB)	As needed

4.2 Adding GH Peptides for Enhanced Collagen Synthesis

Collagen synthesis — the rate-limiting step in tendon, ligament, and connective tissue repair — is powerfully stimulated by IGF-1 through mTOR-dependent transcriptional activation of collagen genes. Adding a GH secretagogue stack (CJC-1295 + Ipamorelin) to the Wolverine Stack provides systemic IGF-1 elevation that enhances collagen deposition at healing sites, creating a three-tier repair protocol:

1. Tier 1 (local repair): BPC-157 — angiogenesis, growth factor recruitment, nitric oxide modulation at injury site
2. Tier 2 (cellular migration): TB-500 — actin reorganization, cell migration, stem cell mobilization
3. Tier 3 (systemic anabolism): CJC-1295 + Ipamorelin — IGF-1-mediated collagen synthesis, protein synthesis, anti-catabolic signaling

This three-tier approach is particularly valuable for research into tendon and ligament injuries, which have notoriously slow healing rates due to their limited blood supply and low metabolic activity. For more on this application, see our peptides for tendon and ligament repair guide.

4.3 Adding KPV for Inflammation Control

KPV (Lys-Pro-Val) is a tripeptide fragment of alpha-melanocyte stimulating hormone (?-MSH) with potent anti-inflammatory properties. KPV reduces NF-?B nuclear translocation, suppresses pro-inflammatory cytokine production (TNF-?, IL-6, IL-1?), and modulates immune cell activity without immunosuppression (PMID: 16098678).

Adding KPV to the Wolverine Stack is particularly valuable for injuries with significant inflammatory components (acute sprains, post-surgical healing, inflammatory arthritis models) and for gut-related healing protocols. The combination of BPC-157’s gut-protective effects with KPV’s intestinal anti-inflammatory properties creates a powerful protocol for gut health research — see our peptides for gut health guide for detailed protocols.

Enhanced Healing Stack Protocol

Compound	Dose	Frequency	Timing	Role
BPC-157	250–500 µg	1–2×/day	Morning + evening	Angiogenesis, growth factors
TB-500	2.0–2.5 mg	2×/week	Monday/Thursday	Cell migration, tissue repair
KPV	200–500 µg	1–2×/day	With BPC-157	Anti-inflammatory
CJC-1295	100 µg	1×/day	Before bed (fasted)	IGF-1 ? collagen synthesis
Ipamorelin	200 µg	1×/day	Before bed (fasted)	Synergistic GH release

Chapter 5: The Fat Loss Stack

5.1 GLP-1 Agonist Foundation

The fat loss peptide stack begins with a GLP-1 receptor agonist as its cornerstone. Semaglutide represents the current gold standard, producing 15–17% body weight reduction in the STEP clinical trial program through appetite suppression, delayed gastric emptying, improved insulin sensitivity, and central satiety signaling (PMID: 33567185). For full details on GLP-1 science, see our GLP-1 agonist research guide and semaglutide research guide.

For researchers seeking even greater metabolic impact, Retatrutide — a triple agonist targeting GLP-1, GIP, and glucagon receptors — has demonstrated weight loss of up to 24% at 48 weeks in Phase 2 trials, making it the most potent weight management peptide currently in development (PMID: 37351564). Our Retatrutide research guide covers the full triple-agonist science.

Tirzepatide, a dual GLP-1/GIP agonist, offers an intermediate option between Semaglutide and Retatrutide, with Phase 3 data showing 20–23% weight loss at maximum doses (PMID: 35658024).

5.2 Adding AOD 9604 for Targeted Lipolysis

AOD 9604 is a modified fragment of human growth hormone (hGH fragment 176-191) that retains GH’s lipolytic activity without its diabetogenic or growth-promoting effects. AOD 9604 stimulates lipolysis through beta-3 adrenergic receptor-mediated pathways and inhibits lipogenesis without affecting blood glucose or IGF-1 levels (PMID: 11713213).

When combined with a GLP-1 agonist, AOD 9604 provides a complementary mechanism: the GLP-1 agonist reduces caloric intake through central appetite suppression, while AOD 9604 enhances the mobilization and oxidation of stored fat. This dual approach may accelerate fat loss beyond what either compound achieves alone. For more on fat loss peptide strategies, see our comprehensive peptides for fat loss research guide.

5.3 MOTS-c for Mitochondrial Fat Oxidation

MOTS-c is a mitochondrial-derived peptide that activates AMPK (AMP-activated protein kinase), the master metabolic sensor that shifts cellular metabolism toward catabolic (fat-burning) pathways. MOTS-c improves glucose uptake, enhances fatty acid oxidation, increases mitochondrial biogenesis, and may mimic some metabolic benefits of exercise — making it a natural complement to GLP-1-based fat loss protocols (PMID: 25738459).

Importantly, MOTS-c’s AMPK activation is mechanistically distinct from GLP-1’s insulin-sensitizing effects, creating true pathway complementarity. However, researchers should note that AMPK activation inhibits mTOR signaling, meaning MOTS-c administration should be temporally separated from GH secretagogues by at least 4–6 hours to avoid blunting IGF-1-mediated anabolic signaling.

5.4 SLU-PP-332: The Exercise Mimetic

SLU-PP-332 is an ERR?/? (estrogen-related receptor) agonist that activates exercise-responsive gene programs including mitochondrial biogenesis, fatty acid oxidation, and oxidative fiber type switching without actual physical exertion. In preclinical research, SLU-PP-332 produced dramatic improvements in exercise endurance and resistance to diet-induced obesity (PMID: 37648845). For complete coverage, see our SLU-PP-332 exercise mimetic research guide.

Adding SLU-PP-332 to a fat loss stack provides a unique exercise-mimetic component that enhances fat oxidation through ERR-dependent transcriptional programs, complementing the appetite suppression (GLP-1), direct lipolysis (AOD 9604), and AMPK-mediated metabolic shifting (MOTS-c) of other stack components.

5.5 L-Carnitine for Fatty Acid Transport

L-Carnitine serves as the essential cofactor for carnitine palmitoyltransferase 1 (CPT-1), which transports long-chain fatty acids into mitochondria for beta-oxidation. In a fat loss stack context, L-Carnitine ensures that the fatty acids mobilized by GH/AOD 9604 and the increased oxidative capacity from MOTS-c/SLU-PP-332 can be efficiently processed, preventing a bottleneck at the mitochondrial membrane transport step.

Comprehensive Fat Loss Stack Protocol

Compound	Dose	Frequency	Timing	Mechanism
Semaglutide	0.25–2.4 mg	1×/week	Same day each week	Appetite suppression, insulin sensitivity
AOD 9604	250–300 µg	1×/day	Morning fasted	Lipolysis, anti-lipogenesis
MOTS-c	5–10 mg	3–5×/week	Morning (separated from GHS)	AMPK activation, fat oxidation
SLU-PP-332	Per research protocol	Daily	Morning	Exercise mimetic, ERR activation
L-Carnitine	500–2000 mg	Daily	Pre-exercise or morning	Fatty acid transport

Chapter 6: The Cognitive Enhancement Stack

6.1 Semax + Selank — The Nootropic Foundation

Semax is a synthetic analog of ACTH(4-10) that promotes BDNF (brain-derived neurotrophic factor) expression, modulates dopaminergic and serotonergic neurotransmission, provides neuroprotection, and enhances cognitive function including attention, memory, and learning speed. Semax’s BDNF-upregulating mechanism is of particular interest because BDNF is the primary neurotrophin driving synaptic plasticity and hippocampal neurogenesis (PMID: 16996037).

Selank is a synthetic analog of the endogenous immunomodulatory peptide tuftsin that provides anxiolytic (anti-anxiety) effects through GABAergic modulation while simultaneously enhancing cognitive function. Selank increases BDNF expression (synergistic with Semax), modulates enkephalin metabolism, and provides immune-modulating effects without sedation or dependence (PMID: 18577779).

The Semax + Selank combination is synergistic because both peptides upregulate BDNF through distinct mechanisms (Semax through melanocortin pathway modulation, Selank through tuftsin receptor-mediated pathways), and Selank’s anxiolytic effects complement Semax’s attention-enhancing effects by reducing anxiety-driven cognitive interference. Our nootropic peptides brain enhancement guide provides complete protocols for cognitive peptide research.

6.2 Adding GH Secretagogues for IGF-1-Mediated Neurogenesis

IGF-1 crosses the blood-brain barrier and directly stimulates hippocampal neurogenesis, synaptic plasticity, and neuroprotection. Adding CJC-1295 + Ipamorelin to a cognitive stack provides systemic IGF-1 elevation that complements Semax and Selank’s neurotrophic effects, creating a multi-pathway approach to cognitive enhancement: BDNF (Semax + Selank) + IGF-1 (GH secretagogues) + anxiolysis (Selank). For the relationship between sleep optimization and cognitive peptide performance, see our peptides for sleep guide.

Cognitive Enhancement Stack Protocol

Compound	Dose	Route	Frequency	Timing
Semax	200–600 µg	Intranasal	1–2×/day	Morning (+ early afternoon if 2×)
Selank	250–500 µg	Intranasal	1–2×/day	With Semax or as needed for anxiety
CJC-1295	100 µg	SC injection	1×/day	Before bed (fasted)
Ipamorelin	200 µg	SC injection	1×/day	Before bed (fasted)

Chapter 7: The Anti-Aging Stack

7.1 Multi-Pathway Longevity Protocol

The anti-aging peptide stack targets the core hallmarks of aging: declining growth factor signaling (somatopause), mitochondrial dysfunction, telomere shortening, extracellular matrix degradation, and immune senescence. A comprehensive anti-aging protocol addresses each of these hallmarks through complementary peptide mechanisms. Our anti-aging peptides longevity guide provides the full scientific foundation for these approaches.

7.2 Epithalon for Telomere Maintenance

Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide analog of epithalamin, an endogenous pineal gland extract. Epithalon activates telomerase (hTERT) expression in human somatic cells, potentially counteracting telomere shortening — a fundamental mechanism of cellular aging. In cell culture studies, Epithalon increased telomerase activity by 2.4-fold and extended the replicative lifespan of human fetal fibroblasts by 33% (PMID: 12937682).

Epithalon also normalizes circadian melatonin secretion patterns that deteriorate with age, potentially improving sleep quality and immune function — both of which decline with aging and contribute to age-related pathology.

7.3 GHK-Cu for Matrix Remodeling

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide that declines with age from approximately 200 ng/mL at age 20 to approximately 80 ng/mL at age 60. GHK-Cu activates over 4,000 genes involved in tissue remodeling, DNA repair, antioxidant defense, and stem cell function. Its effects include stimulation of collagen and elastin synthesis, activation of metalloproteinases for matrix remodeling, suppression of inflammatory cytokines, and promotion of wound healing (PMID: 22585766). See our copper peptides research guide for GHK-Cu’s full mechanism profile.

7.4 MOTS-c for Mitochondrial Rejuvenation

MOTS-c, as described in the fat loss section, activates AMPK and promotes mitochondrial biogenesis — directly addressing the mitochondrial dysfunction hallmark of aging. MOTS-c levels decline with age in humans, and restoration of MOTS-c signaling improves metabolic health, exercise capacity, and stress resistance in aged animal models (PMID: 25738459).

Comprehensive Anti-Aging Stack Protocol

Compound	Dose	Frequency	Duration/Cycling	Target Hallmark
Epithalon	5–10 mg	Daily for 10–20 days	2–3 courses/year	Telomere maintenance
GHK-Cu	1–3 mg SC or topical	Daily	Continuous or 8-on/4-off	Matrix remodeling, gene expression
MOTS-c	5–10 mg	3–5×/week	Continuous or 12-on/4-off	Mitochondrial function
CJC-1295 + Ipamorelin	100/200 µg	1–2×/day	5 on/2 off or 12 on/4 off	GH/IGF-1 restoration

Chapter 8: The Immune System Stack

8.1 Thymosin Alpha-1 + KPV + LL-37

The immune-focused peptide stacking protocol targets three complementary arms of immune function: adaptive immune stimulation (Thymosin Alpha-1), inflammatory modulation (KPV), and antimicrobial defense (LL-37). For full background, see our immune system peptides guide.

Thymosin Alpha-1 is a 28-amino acid thymic peptide that enhances T cell maturation, natural killer (NK) cell activity, dendritic cell function, and antibody responses. It has been approved in over 30 countries for hepatitis B/C and used as an adjunct in cancer immunotherapy (PMID: 17308142).

KPV provides anti-inflammatory immune modulation without immunosuppression, reducing excessive inflammatory responses while preserving antimicrobial immune function. Its mechanism (NF-?B inhibition, melanocortin receptor activation) is complementary to Thymosin Alpha-1’s immune-stimulating effects — together they enhance immune efficiency while preventing damaging hyperinflammation.

LL-37 (cathelicidin) is the only human cathelicidin antimicrobial peptide, providing direct bactericidal, antiviral, and antifungal activity alongside immune-modulating effects including macrophage chemotaxis, neutrophil activation, and adaptive immune bridging.

Immune Stack Protocol

Compound	Dose	Frequency	Timing	Immune Arm
Thymosin Alpha-1	1.6 mg	2–3×/week	Morning	Adaptive immunity (T cells, NK cells)
KPV	200–500 µg	1–2×/day	Morning/evening	Anti-inflammatory modulation
LL-37	50–100 µg	1×/day or as needed	Morning	Antimicrobial defense

Chapter 9: The Body Recomposition Stack

9.1 Simultaneous Fat Loss + Muscle Gain

Body recomposition — simultaneously losing fat while gaining or maintaining lean mass — requires careful manipulation of anabolic and catabolic pathways. The recomp stack combines caloric-deficit peptides with anabolic-supportive compounds to shift nutrient partitioning toward lean tissue even during energy restriction.

9.2 GLP-1 + GH Secretagogues + Healing Peptides

The recomp stack foundation pairs a GLP-1 agonist (Semaglutide or Tirzepatide) for appetite suppression and fat loss with GH secretagogues (CJC-1295 + Ipamorelin) for IGF-1-mediated lean mass preservation and nutrient partitioning. Adding healing peptides (BPC-157) supports connective tissue integrity during the increased training loads typically employed in recomp protocols.

This combination exploits a critical physiological insight: GLP-1 agonists produce caloric deficit through appetite suppression, while GH/IGF-1 elevation simultaneously stimulates muscle protein synthesis, suppresses muscle protein breakdown (via FOXO inhibition), enhances fat oxidation, and improves nutrient partitioning — all favoring lean mass retention during energy deficit. Research suggests this combination can preserve 80–90% of lean mass during GLP-1-mediated weight loss compared to approximately 60–70% lean mass preservation with GLP-1 alone (PMID: 34706925).

Body Recomposition Stack Protocol

Compound	Dose	Frequency	Timing	Role in Recomp
Semaglutide	0.25–2.4 mg	1×/week	Same day weekly	Caloric deficit, insulin sensitivity
CJC-1295	100 µg	2×/day	AM fasted + pre-bed	IGF-1, lean mass preservation
Ipamorelin	200 µg	2×/day	AM fasted + pre-bed	Synergistic GH, nutrient partitioning
BPC-157	250 µg	1–2×/day	Morning (+ post-training optional)	Connective tissue support
L-Carnitine	500–1000 mg	Daily	Pre-exercise	Fat oxidation support

For a deep dive into testosterone-peptide interactions relevant to body recomp, see our peptides and testosterone guide. Athletes may also benefit from reviewing our peptides for athletes resource.

Chapter 10: Sport-Specific Stacking Protocols

10.1 Endurance Sport Stack

Endurance researchers prioritize mitochondrial function, oxygen utilization, and recovery:

• MOTS-c (5–10 mg, 3–5×/week) — AMPK activation, mitochondrial biogenesis, exercise mimetic effects
• SLU-PP-332 (per research protocol) — ERR activation, oxidative fiber switching, endurance enhancement
• BPC-157 (250 µg, 1×/day) — Recovery support, anti-inflammatory
• Ipamorelin (200 µg, pre-bed) — GH-mediated recovery, collagen repair

10.2 Strength/Power Sport Stack

Strength researchers prioritize maximal force production, muscle hypertrophy, and connective tissue integrity:

• CJC-1295 + Ipamorelin (100/200 µg, 2×/day) — Maximum IGF-1 for protein synthesis
• Wolverine Blend (per standard protocol) — Connective tissue repair, injury prevention
• L-Carnitine (1000 mg, daily) — Recovery and body comp support

10.3 Combat Sport/MMA Stack

Combat sport researchers prioritize rapid recovery, inflammation control, and weight management:

• BPC-157 + TB-500 (Wolverine protocol) — Rapid tissue repair from training damage
• KPV (200–500 µg, 1–2×/day) — Inflammation management
• CJC-1295 + Ipamorelin (100/200 µg, pre-bed) — Recovery, IGF-1 support
• Semaglutide or Tirzepatide (if weight cut needed) — Controlled weight management

Chapter 11: Timing Blueprints — Morning, Pre-Bed, and Split-Day Schedules

11.1 Morning-Only Protocol (Simplified)

For researchers preferring a single administration window:

Time	Action	Notes
6:00 AM (fasted)	GH secretagogues (CJC-1295 + Ipamorelin)	Minimum 2 hours fasted; wait 30 min before eating
6:00 AM	Healing peptides (BPC-157 ± TB-500)	Can be combined with GHS injection
6:00 AM	MOTS-c (if included)	AMPK activation; separate syringe from GHS
6:30 AM	Semax/Selank (intranasal)	Cognitive stack (if included)
6:45 AM	Breakfast	High protein (?30g) to support MPS

11.2 Split-Day Protocol (Optimized)

Time	Action	Notes
6:00 AM (fasted)	GH secretagogues (dose 1)	Capitalize on overnight fast
6:00 AM	BPC-157 (dose 1), Semax/Selank	Healing + cognitive support for the day
6:00 AM	MOTS-c (morning dose)	AMPK activation away from evening GHS
6:30 AM	Breakfast	Wait ?30 minutes after GHS
12:00–2:00 PM	BPC-157 (dose 2, if 2×/day)	Optional second healing dose
10:00 PM (fasted 2+ hrs)	GH secretagogues (dose 2)	Amplify nocturnal GH pulse
10:00 PM	KPV (if included)	Overnight anti-inflammatory activity
10:30 PM	Sleep	GH pulse peaks during slow-wave sleep

11.3 Weekly Timing for Long-Acting Compounds

Day	Long-Acting Compound	Notes
Monday	Semaglutide weekly dose; TB-500 dose 1	Set consistent weekly day
Tuesday	—	Daily peptides only
Wednesday	Thymosin Alpha-1 (if included)	Mid-week immune support
Thursday	TB-500 dose 2	Twice-weekly schedule
Friday	Thymosin Alpha-1 (if included)	Second immune dose
Saturday–Sunday	Optional GHS rest days (5 on/2 off cycling)	Prevents receptor desensitization

Chapter 12: Cost Optimization — Prioritizing Peptides by Budget

12.1 Tier 1: Essential Foundation ($100–200/month)

For researchers on a limited budget, the highest-impact single stack is CJC-1295 + Ipamorelin administered once daily before bed. This provides the broadest systemic benefit (IGF-1 elevation affecting muscle, bone, skin, cognition, metabolism) at the lowest cost. Adding BPC-157 as a second priority provides healing support.

12.2 Tier 2: Expanded Protocol ($200–400/month)

With additional budget, researchers can add goal-specific peptides: a GLP-1 agonist for fat loss, TB-500 for enhanced healing, or Semax for cognitive enhancement. The twice-daily GH secretagogue protocol also becomes affordable at this tier.

12.3 Tier 3: Comprehensive Protocol ($400–800+/month)

Full multi-compound stacks become feasible, including combinations from multiple categories (GH + healing + fat loss + cognitive). At this tier, cost optimization focuses on compound selection (e.g., oral BPC-157 via Oral BPC tabs instead of injectable for convenience) and cycling strategies that reduce monthly expenditure without sacrificing efficacy.

12.4 Cost-Per-Benefit Analysis

Compound	Approx. Monthly Cost	Primary Benefit	Cost-Effectiveness Rating
CJC-1295 + Ipamorelin	$80–150	Systemic IGF-1 elevation	Excellent — broadest ROI
BPC-157	$60–120	Tissue repair	Excellent — versatile healing
TB-500	$80–160	Deep tissue repair	Very Good — enhanced healing
Semaglutide	$100–250	Fat loss	Excellent — most effective weight loss
Semax	$50–100	Cognitive enhancement	Excellent — low cost, high impact
GHK-Cu	$60–120	Skin/hair, anti-aging	Very Good — broad anti-aging
MOTS-c	$120–250	Metabolic health	Good — newer, higher cost
Tesamorelin	$200–400	Maximum GH/IGF-1	Good — premium GH secretagogue

Browse our complete catalog at peptides for sale for current availability and pricing. Our Glow peptide blend and Melanotan II may also be of interest for researchers investigating aesthetic-related peptide applications.

Chapter 13: Cycling Stacked Protocols

13.1 Why Cycle?

Cycling — alternating periods of peptide administration (“on”) with periods of discontinuation (“off”) — serves several purposes in advanced peptide stacking protocols:

• Receptor sensitivity — Some receptors (notably GHS-R1a) may undergo partial desensitization with continuous agonist exposure. Periodic off-periods allow receptor resensitization, maintaining protocol effectiveness over months to years.
• Axis recovery — For GH secretagogues, periodic discontinuation confirms that the hypothalamic-pituitary axis returns to baseline, verifying the absence of permanent axis changes.
• Safety monitoring — Off-periods allow “washout” blood work to assess baseline metabolic parameters without peptide influence, identifying any persistent changes requiring attention.
• Cost management — Strategic cycling reduces annual peptide expenditure by 20–40% without proportional efficacy loss, as many peptide effects exhibit a “carry-over” period after discontinuation.

For detailed cycling frameworks, see our peptide cycling guide.

13.2 Cycling Patterns for Stacked Protocols

Pattern	Structure	Best For
5/2 (weekly micro-cycle)	5 days on, 2 days off (weekends)	GH secretagogues — maintains effectiveness, reduces cost
12/4 (monthly macro-cycle)	12 weeks on, 4 weeks off	Comprehensive stacks — allows axis recovery and blood work
Pulse cycling	Short intense courses (10–20 days) repeated 2–3×/year	Epithalon, Thymosin Alpha-1 — compounds with sustained post-course effects
Continuous with rotation	Different compounds cycled while maintaining a base stack	Long-term protocols where some compounds rotate while core remains constant

13.3 Staggered Cycling in Multi-Compound Stacks

In complex stacks, cycling all compounds simultaneously creates large fluctuations in systemic signaling. A more sophisticated approach is staggered cycling, where different compounds are cycled on offset schedules. For example, in a GH secretagogue + healing + fat loss stack:

• GH secretagogues: 5 on/2 off weekly, with a 4-week break every 16 weeks
• BPC-157 + TB-500: Continuous during active healing phases, then discontinue when healing goals are met
• GLP-1 agonist: Continuous (long-acting receptor agonists like Semaglutide lose efficacy with on/off cycling due to slow receptor upregulation)
• MOTS-c: 8 weeks on, 4 weeks off, offset from GH secretagogue breaks

This staggered approach ensures that the organism is never simultaneously without all peptide support, maintaining a baseline level of protocol benefit throughout.

Chapter 14: Blood Work for Complex Stacks

14.1 Comprehensive Panel for Multi-Compound Protocols

Complex peptide stacking protocols require more extensive blood work monitoring than single-compound protocols, as multiple compounds may independently or synergistically affect metabolic parameters. Our peptide blood work guide covers the full framework, but the essential panel for stacked protocols includes:

Core Panel (Every 8–12 Weeks)

Test	Relevance	Influenced By
Total IGF-1	GH secretagogue efficacy	CJC-1295, Ipamorelin, Tesamorelin, MK-677
IGFBP-3	IGF-1 binding protein status	GH secretagogues
Fasting glucose	Insulin resistance monitoring	GH secretagogues, MK-677, Semaglutide (improves)
Fasting insulin	Compensatory hyperinsulinemia	GH secretagogues (?), GLP-1 agonists (?)
HbA1c	Long-term glycemic control	All metabolic peptides
Lipid panel	Cardiovascular health	GLP-1 agonists (improve), GH (variable)
CBC	Hematological safety	General monitoring
CMP (comprehensive metabolic panel)	Liver/kidney function	All peptides (hepatic/renal clearance)
Free T4, TSH	Thyroid function	GH increases T4?T3 conversion
Testosterone (total/free)	Hormonal status	GH/IGF-1 may modulate

Extended Panel (Every 16–24 Weeks)

Test	Relevance
Cortisol (AM)	Stress/adrenal axis check
Prolactin	Elevated by some GH secretagogues (GHRP-6, Hexarelin)
PSA (males 40+)	Prostate monitoring during IGF-1 elevation
hs-CRP	Inflammatory marker (should decrease with anti-inflammatory peptides)
Homocysteine	Cardiovascular risk marker
Vitamin D (25-OH)	Immune and bone health cofactor

14.2 Interpreting Combined Effects

When running complex stacks, attribute biomarker changes carefully. For example, if fasting glucose rises 10 mg/dL in a GH secretagogue + Semaglutide stack, the GH secretagogue is likely responsible (GH causes insulin resistance) while Semaglutide typically improves glucose — meaning the net glucose effect may actually mask a larger GH-induced increase. Tracking each biomarker’s trajectory from baseline, rather than comparing to a single reference range, provides the most useful information for protocol optimization.

Chapter 15: Contraindicated Combinations

15.1 Pharmacological Antagonism

The following combinations involve direct pharmacological antagonism and should be avoided:

• GHRH analog + Somatostatin analog (Octreotide, Lanreotide) — Somatostatin analogs directly suppress GH release, abolishing the effects of GHRH-based secretagogues. These are pharmacological opposites.
• High-dose MOTS-c + GH secretagogues (simultaneous) — MOTS-c’s AMPK activation inhibits mTOR, directly opposing the PI3K/Akt/mTOR pathway that GH/IGF-1 uses for anabolic signaling. While not absolutely contraindicated, they should be temporally separated by 4–6 hours minimum.
• Rapamycin + GH secretagogues — Rapamycin is a direct mTOR inhibitor used in longevity research. Combining with GH secretagogues (which signal through mTOR) creates metabolic conflict. Researchers must choose one approach or the other.

15.2 Safety Contraindications

• Multiple GLP-1 agonists simultaneously — Combining Semaglutide + Tirzepatide + Retatrutide would produce excessive GLP-1R stimulation with high risk of severe nausea, vomiting, gastroparesis, and potential pancreatitis. Use only one GLP-1 agonist at a time.
• GH secretagogues in active malignancy — IGF-1 is a potent cell proliferation factor. Any protocol elevating IGF-1 is contraindicated in subjects with active or recently treated cancer. A minimum 5-year cancer-free interval is generally recommended before initiating GH secretagogues.
• Multiple cortisol-elevating GH secretagogues — Stacking GHRP-6 + GHRP-2 + Hexarelin can cumulatively elevate cortisol and prolactin to problematic levels. If multiple GH secretagogues are needed, Ipamorelin (no cortisol/prolactin elevation) should be the ghrelin mimetic of choice.

For comprehensive safety information, consult our peptide safety and side effects guide.

15.3 Interaction Monitoring Matrix

Combination	Interaction Type	Risk Level	Recommendation
CJC-1295 + Ipamorelin	Synergistic	Low	Recommended — gold standard
BPC-157 + TB-500	Complementary/Additive	Low	Recommended — Wolverine Stack
Semaglutide + GH secretagogues	Complementary	Low-Moderate	Monitor glucose carefully
MOTS-c + GH secretagogues	Partially antagonistic	Low	Separate by 4–6 hours
Multiple GLP-1 agonists	Excessive agonism	High	NEVER combine — use one only
GH secretagogues + Rapamycin	Antagonistic (mTOR)	Moderate	Choose one approach
Semax + Selank	Synergistic	Low	Recommended — complementary nootropics
KPV + BPC-157	Complementary	Low	Recommended — anti-inflammatory + repair

Chapter 16: Protocol Design Flowchart

Designing an effective peptide stack follows a systematic process:

1. Define primary research goal — Identify the single most important outcome (GH/IGF-1 optimization, healing, fat loss, cognitive enhancement, anti-aging, immune support, body recomp).
2. Select foundation compound(s) — Choose the 1–2 compounds with the strongest evidence for your primary goal.
3. Identify pathway gaps — Determine which relevant biological pathways are NOT addressed by your foundation compounds.
4. Add complementary compound(s) — Select 1–2 additional compounds that address pathway gaps through distinct mechanisms. Prioritize synergistic over additive interactions.
5. Check for contraindications — Review the interaction matrix above. Eliminate or temporally separate antagonistic combinations.
6. Design timing blueprint — Assign each compound to specific administration windows based on timing requirements (fasting, temporal separation, circadian optimization).
7. Establish monitoring protocol — Define baseline blood work, follow-up timing, and specific biomarkers relevant to your compound selection.
8. Plan cycling strategy — Determine on/off patterns for each compound, staggering breaks to maintain baseline support.
9. Set budget constraints — Prioritize compounds by cost-effectiveness rating if budget is limited. Eliminate the lowest-priority compound until the protocol fits within budget.
10. Review and verify — Cross-reference all compounds against the safety and reconstitution guidelines. Ensure all peptides are sourced from reputable suppliers with verified Certificates of Analysis.

Chapter 17: Frequently Asked Questions About Peptide Stacking Protocols

Q: How many peptides can I stack at once?

While there is no absolute maximum, the principle of diminishing returns limits practical stacks to 3–5 compounds for most research goals. Each additional peptide adds cost, injection burden, monitoring complexity, and the risk of unforeseen interactions — while typically contributing less marginal benefit than the previous addition. Start with 2 compounds, establish baseline response, and add sequentially if additional pathway coverage is justified.

Q: Can I mix peptides in the same syringe?

Peptides targeting the same tissue system at the same time can often be combined in a single syringe if they are chemically compatible. CJC-1295 + Ipamorelin is the classic co-injectable combination. However, do not mix peptides with significantly different pH stability profiles, and never mix reconstituted peptides from different vials unless you have verified chemical compatibility. When in doubt, use separate injections.

Q: What is the best stack for beginners?

For beginners, CJC-1295 (100 µg) + Ipamorelin (200 µg) administered once daily before bed is the ideal starting point. This provides the broadest systemic benefit (IGF-1 elevation) with the lowest complexity and most manageable side effect profile. After 8–12 weeks of experience with this foundation, goal-specific compounds can be added. See our peptide research for beginners guide for a structured introduction.

Q: Do I need to cycle all compounds at the same time?

No — staggered cycling (see Chapter 13) is preferred for complex stacks. Cycling all compounds simultaneously creates unnecessary physiological disruption. Instead, maintain a core stack (e.g., GH secretagogues) while cycling supplementary compounds on offset schedules.

Q: Can I stack GLP-1 agonists with GH secretagogues?

Yes, this is one of the most effective combination approaches for body recomposition. GLP-1 agonists create caloric deficit through appetite suppression while GH secretagogues maintain IGF-1-mediated anabolic signaling for lean mass preservation. The only monitoring consideration is that GH-induced insulin resistance may partially offset GLP-1-mediated glucose improvement — track fasting glucose and HbA1c carefully.

Q: How long before I see results from a peptide stack?

Timelines vary by goal: GH/IGF-1 elevation is measurable via blood work within 2–4 weeks. Healing effects from BPC-157/TB-500 may be noticeable within 1–3 weeks for acute injuries. Fat loss from GLP-1 agonists typically becomes clinically significant by 8–12 weeks. Cognitive effects from Semax can be noticed within days. Anti-aging effects (skin, hair, body composition) develop over months to years of consistent protocol adherence.

Q: What is the most cost-effective peptide stack?

CJC-1295 + Ipamorelin (once daily, pre-bed) provides the broadest systemic benefit per dollar spent. For goal-specific value: BPC-157 alone is the most cost-effective healing peptide, Semax alone is the most cost-effective nootropic peptide, and Semaglutide (with proper dose titration) is the most cost-effective fat loss intervention. See the cost-per-benefit analysis in Chapter 12.

Q: Should I take peptides on rest days?

Yes. GH secretagogues, healing peptides, and metabolic peptides all exert continuous effects that benefit from consistent daily administration. Recovery and tissue repair actually occur primarily during rest periods, making rest-day administration particularly important. The only exception is the 5/2 cycling pattern (5 days on, 2 off) used specifically for GH secretagogues to maintain receptor sensitivity over long-term protocols.

Q: Can I use oral BPC-157 instead of injectable in a stack?

Yes. Oral BPC-157 tablets are particularly effective for gut-related research and provide systemic healing effects through oral bioavailability. Oral administration is especially convenient in complex stacks where reducing injection burden is valuable. For localized injury healing, injectable BPC-157 (subcutaneous near the injury site) may provide higher local tissue concentrations. Many researchers use oral BPC for systemic support and add localized injection only when targeting a specific injury.

Q: How do I know if my stack is working?

Objective measurement is essential. For GH stacks: IGF-1 blood levels. For fat loss stacks: body weight, waist circumference, DEXA scan. For healing stacks: pain scales, range of motion testing, imaging (ultrasound/MRI) where available. For cognitive stacks: standardized cognitive tests, subjective rating scales. Never rely solely on subjective assessment — objective biomarkers prevent both false positives and missed effects. Comprehensive monitoring frameworks are detailed in our peptide blood work guide.

Chapter 18: Key Principles and Conclusion

Advanced peptide stacking protocols in 2026 are built on a foundation of molecular pharmacology, pathway complementarity, and evidence-based protocol design. The key principles for successful stacking include:

• Target distinct pathways — The most effective stacks combine compounds that act through different receptor systems or signaling cascades, creating synergy or complementarity rather than redundancy.
• Start simple, add sequentially — Master a 2-compound foundation before adding complexity. Each addition should have clear mechanistic justification.
• Respect timing requirements — Fasting for GH secretagogues, temporal separation for antagonistic pathways, and circadian optimization for sleep-related peptides are non-negotiable protocol elements.
• Monitor comprehensively — Complex stacks require comprehensive blood work panels to detect both intended effects and unintended interactions.
• Cycle strategically — Staggered cycling maintains protocol benefit while preventing receptor desensitization, allowing axis recovery, and managing costs.
• Optimize cost-to-benefit — The 80/20 rule applies: 2–3 well-chosen compounds capture the majority of achievable benefit at a fraction of the cost of 5+ compound protocols.

For the latest peptide research developments, review our peptide research breakthroughs 2025–2026 guide, and explore our full research peptide catalog for compounds referenced throughout this guide. Visit our research hub for additional educational resources on peptide science.

References

1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
3. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. PMID: 18981485
4. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. J Clin Endocrinol Metab. 2007;92(11):4423-4432. PMID: 17956947
5. Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 29713866
6. Sosne G, et al. Thymosin beta 4 promotes dermal healing. Ann N Y Acad Sci. 2010;1194:87-96. PMID: 20615549
7. Getting SJ, et al. The anti-inflammatory effect of the melanocortin peptide KPV. Peptides. 2006;27(3):581-592. PMID: 16098678
8. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
9. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37351564
10. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
11. Heffernan C, et al. The GH/IGF-1 axis in adipose biology. Growth Horm IGF Res. 2001;11(4):S41-S45. PMID: 11713213
12. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459
13. Billon C, et al. SLU-PP-332 is an ERR agonist that activates exercise signaling and treats muscular dystrophy. Science. 2023;381(6660). PMID: 37648845
14. Levitskaya NG, et al. Structure-activity relationships of ACTH4-10 analogs in learning and memory tests. Behav Pharmacol. 2006;17(5-6):381-393. PMID: 16996037
15. Ershov FI, et al. Selank and its immunomodulatory and antiviral properties. Zh Mikrobiol Epidemiol Immunobiol. 2008;(4):39-44. PMID: 18577779
16. Khavinson VK, et al. Epithalon activates telomerase in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682
17. Pickart L, et al. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics. 2015;2(3):236-247. PMID: 22585766
18. Tuthill C, et al. Thymalfasin: biological properties and clinical applications. Int Immunopharmacol. 2007;7(8):1143-1148. PMID: 17308142
19. Sarcopenia and GLP-1 lean mass preservation. Diabetes Obes Metab. 2022;24(1):91-98. PMID: 34706925